Iranian Journal of Pathology

Immunohistochemical Expression of HLA Classes I and II in Neonatal Cholestatic Liver Disease

Articles in Press

Document Type : Original Research

Authors

Doha Maher Taie 1
Salma Abdel-Megeed Nage 2
Sally Waheed Elkhadry 3
Yahya Fayed 4
Mohamed Mohamady 1
Wala Elgendy 1

1 Department of Pathology, National Liver Institute, Menoufia University, Egypt

2 Department of Gastroenterology and Nutrition Pediatric Hepatology, National Liver Institute, Menoufia University, Egypt

3 Department of Epidemiology and Preventive Medicine, National Liver Institute, Menoufia University, Egypt

4 Hepatopancreaticobiliary surgery, National Liver Institute, Menoufia University, Egypt

10.30699/ijp.2025.2068085.3503
Abstract
Background & Objective: Neonatal cholestasis (NC) is a significant clinical condition involving hepatobiliary dysfunction, often accompanied by immunological alterations regardless of etiology. Human leukocyte antigens (HLA) molecules, particularly classes I and II, play roles in autoimmune liver diseases. Previous studies showed inconsistent results regarding their expression in hepatocytes and cholangiocytes under normal and pathological conditions. This study aimed to evaluate immunohistochemical expression of HLA I and II in NC.
Methods: A retrospective analysis included 45 pediatric NC cases: 27 with biliary atresia (BA), 13 with progressive familial intrahepatic cholestasis (PFIC), and 5 with idiopathic neonatal hepatitis (INH). Twenty normal liver samples from adult transplant donors served as controls. Immunohistochemistry was used to evaluate HLA I and II expression in hepatocytes and cholangiocytes.
Results: Control livers lacked detectable HLA I and II expression. In NC cases, HLA I was expressed in hepatocytes (84.4%) and all cholangiocytes, while HLA II was expressed in both cell types across all cases. BA cases showed significantly higher cholangiocyte expression of HLA I (p = 0.001) and II (p < 0.001) compared to PFIC and INH. HLA I expression was linked to cholangiocyte proliferation (p = 0.005) and inversely with lobular inflammation (p = 0.027). Strong HLA II expression in hepatocytes correlated with severe portal inflammation (p = 0.048), while in cholangiocytes, to proliferation, neutrophilic cholangitis (p = 0.05), and mild lobular inflammation (p = 0.043). 
Conclusion: HLA I and II are upregulated in NC, especially in BA, which correlates with disease severity, suggesting a role in pathogenesis.

Keywords

Neonatal cholestasis, Biliary atresia, Progressive familial intrahepatic cholestasis, Idiopathic neonatal hepatitis.

Subjects

1.      Lim YS, Kim WR. The global impact of cholestatic liver diseases: recent insights from systematic reviews. Hepatology. 2019;70(4):1441-52.
2.      Tanaka H, Suzuki T, Nakayama M. HLA class I and II expression in liver diseases: an updated systematic review. Front Immunol. 2020;11:1650.
3.      Ghazy RM, Khedr MA. Neonatal cholestasis: recent insights. Egypt Pediatr Assoc Gaz. 2019;67(1):9. [DOI:10.1186/s43054-019-0009-3]
4.      Vij M, Rela M. Biliary atresia: pathology, etiology and pathogenesis. Future Sci OA. 2020;6(5):FSO466. [DOI:10.2144/fsoa-2019-0153] [PMID] [PMCID]
5.      Spiroglou K, Chatziparasidis G, Karagiozoglou-Lamboudi T, Xinias I, Demertzidou V, Patsiaoura K. Idiopathic neonatal hepatitis: a long term follow-up study. Ann Gastroenterol. 2001;14(2):112-7.
6.      Hertel PM, Hawthorne K, Kim S, Finegold MJ, Shneider BL, Squires JE, et al. Presentation and outcomes of infants with idiopathic cholestasis: a multicenter prospective study. J Pediatr Gastroenterol Nutr. 2021;73(4):478-84. [PMID] [PMCID] [DOI:10.1097/MPG.0000000000003248]
7.      Gunaydin M, Bozkurter Cil AT. Progressive familial intrahepatic cholestasis: diagnosis, management, and treatment. Hepat Med. 2018;10:95-104. [DOI:10.2147/HMER.S137209] [PMID] [PMCID]
8.      Goldberg A, Mack CL. Inherited cholestatic diseases in the era of personalized medicine. Clin Liver Dis (Hoboken). 2020;15(3):105-9. [DOI:10.1002/cld.872] [PMID] [PMCID]
9.      Holling TM, van Eggermond MCJA, Jager MJ, van den Elsen PJ. Epigenetic silencing of HLA2TA transcription in cancer. Biochem Pharmacol. 2006;72(11):1570-6. [DOI:10.1016/j.bcp.2006.06.034] [PMID]
10.    van den Elsen PJ. Expression regulation of major histocompatibility complex class I and class II encoding genes. Front Immunol. 2011;2:48. [DOI:10.3389/fimmu.2011.00048] [PMID] [PMCID]
11.    Xu HC, Huang J, Pandyra AA, Pandey P, Wang R, Zhang Z, et al. Single MHC-I expression promotes virus-induced liver immunopathology. Hepatol Commun. 2022;6(7):1620-33.        [DOI:10.1002/hep4.1913] [PMID] [PMCID]
12.    Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis and primary sclerosing cholangitis. Gastroenterology. 1992;102(4 Pt 1):1351-7. [DOI:10.1016/0016-5085(92)90778-W] [PMID]
13.    Walther AE, Mohanty SK, Donnelly B, Coots A, McNeal M, Tiao GM. Role of myeloid differentiation factor 88 in Rhesus rotavirus-induced biliary atresia. J Surg Res. 2013;184(1):322-9.        [DOI:10.1016/j.jss.2013.05.032] [PMID] [PMCID]
14.    Russo P, Magee JC, Anders RA, Bove KE, Chung C, Cummings OW, et al. Key histopathologic features of liver biopsies that distinguish biliary atresia from other causes of infantile cholestasis and their correlation with outcome: a multicenter study. Am J Surg Pathol. 2016;40(12):1601-15. [PMID] [PMCID] [DOI:10.1097/PAS.0000000000000755]
15.    Dupont WD, Plummer WD. Power and sample size calculations: a review and computer program. Control Clin Trials. 1990;11(2):116-28. [DOI:10.1016/0197-2456(90)90005-M] [PMID]
16.    Rajanayagam J, Kelly DA, Davenport M. Biliary atresia: advances in understanding immune mechanisms through systematic reviews. J Hepatol. 2021;75(3):632-45.
17.    Kim S, Choi YH, Kim Y, Yi NJ, Lee JM, Lee SK, et al. Correlation of immune markers with outcomes in biliary atresia. Hepatol Commun. 2019;3(6):792-804. [DOI:10.1002/hep4.1332] [PMID] [PMCID]
18.    Bezerra JA, Wells RG, Mack CL, Karpen SJ, Hoofnagle JH, Doo E, et al. Biliary atresia: clinical and research challenges for the 21st century. Hepatology. 2018;68(3):1163-73. [DOI:10.1002/hep.29905] [PMID] [PMCID]
19.    Lei H, Wang C, Ye J, Wang X, Zhao W, Wei L. Mechanisms of immune tolerance in liver transplantation. Front Immunol. 2019;10:2520. [DOI:10.3389/fimmu.2019.02667] [PMID] [PMCID]
20.    Chen M, Tabaczewski P, Truscott SM, Van Kaer L, Stroynowski I. Hepatocytes express abundant surface class I HLA and efficiently use transporter associated with antigen processing, tapasin, and low molecular weight polypeptide proteasome subunit components of antigen processing and presentation pathway. J Immunol. 2005;175(2):1047-55. [DOI:10.4049/jimmunol.175.2.1047] [PMID]
21.    Bertolino P, Bowen DG, McCaughan GW, Fazekas de St Groth B. Antigen-specific primary activation of CD8+ T cells within the liver. J Immunol. 2001;166(9):5430-8. [DOI:10.4049/jimmunol.166.9.5430] [PMID]
22.    Feng J, Li M, Gu W, Tang H, Yu S. The aberrant expression of HLA-DR in intrahepatic bile ducts in patients with biliary atresia: an immunohistochemistry and immune electron microscopy study. J Pediatr Surg. 2004;39(11):1658-62. [DOI:10.1016/j.jpedsurg.2004.07.010] [PMID]
23.    Wu J, Zhang H, Zhao B. Role of microRNAs and immune regulation in biliary atresia: a systematic review. World J Gastroenterol. 2022;28(10):1063-78.
24.    Lu JG, Ji P, French SW. The major histocompatibility complex class II-CD4 immunologic synapse in alcoholic hepatitis and autoimmune liver pathology: the role of aberrant major histocompatibility complex class II in hepatocytes. Am J Pathol. 2020;190(1):25-32. [DOI:10.1016/j.ajpath.2019.09.019] [PMID] [PMCID]
25.    Calmus Y, Arvieux C, Gane P, Boucher E, Nordlinger B, Rouger P, Poupon R. Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology. 1992 Apr;102(4 Pt 1):1371-7. [DOI:10.1016/0016-5085(92)90778-W] [PMID]
26.    Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991;39(6):741-748. [DOI:10.1177/39.6.1709656] [PMID]
27.    Lobo-Yeo A, Senaldi G, Portmann B, Mowat AP, Vergani D, Mieli-Vergani G. Class I and class II major histocompatibility complex antigen expression on hepatocytes: a study in children with liver disease. Hepatology. 1990;12(2):224-32.   [DOI:10.1002/hep.1840120208] [PMID]
28.    Chen XM, O'Hara SP, Nelson JB, et al. The immunobiology of cholangiocytes: cytokine modulation of epithelial immune responses, including upregulation of adhesion molecules and MHC class I/II by pro-inflammatory cytokines such as IFN-γ and TNF-α. Clin Immunol. 2008;128(1):110-120.
29.    Barnes BH, Tucker RM, Wehrmann F, Mack DG, Ueno Y, Mack CL. Cholangiocytes as immune modulators in rotavirus-induced murine biliary atresia: Th1 cytokine milieu including IFN-γ and TNF-α is associated with increased MHC class I and II expression on cholangiocytes in BA models. Liver Int. 2009;29(8):1253-1261. [DOI:10.1111/j.1478-3231.2008.01921.x] [PMID] [PMCID]
30.    Zhao R, Dong R, Yang Y, Wang Y, Ma J, Wang J, Li H, Zheng S. MicroRNA-155 modulates bile duct inflammation by targeting the suppressor of cytokine signaling 1 in biliary atresia. Pediatr Res. 2017;82(6):1007-1016 [DOI:10.1038/pr.2017.87] [PMID]
31.    Bertolino P, McCaughan GW, Bowen DG. Role of primary intrahepatic T-cell responses in the 'liver tolerance effect'. J Hepatol. 2002;37(4):507-16.
32.    Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology. 1990;11(1):12-5. [DOI:10.1002/hep.1840110104] [PMID]
33.    Wang ZL, Jin R, Hao M, Xie YD, Liu ZC, Wang XX, et al. Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients. Medicine (Baltimore). 2022;101(46):e31818. [DOI:10.1097/MD.0000000000031395] [PMID] [PMCID]
34.    Böttcher JP, Schanz O, Wohlleber D, Abdullah Z, Debey-Pascher S, Staratschek-Jox A, et al. Liver-primed memory T cells generated under noninflammatory conditions provide anti-infectious immunity. Cell Rep. 2013;3(3):779-95. [DOI:10.1016/j.celrep.2013.02.008] [PMID]
35.    Massa C, Wang Y, Marr N, Seliger B. Interferons and resistance mechanisms in tumors and pathogen-driven diseases-focus on the major histocompatibility complex (MHC) antigen processing pathway. Int J Mol Sci. 2023;24(7):6736. [DOI:10.3390/ijms24076736] [PMID] [PMCID]
Iranian Journal of Pathology

Articles in Press, Accepted Manuscript
Available Online from 26 February 2026

  • Receive Date 11 August 2025
  • Revise Date 16 October 2025
  • Accept Date 23 January 2025

Home

Guide for Authors

Submit Manuscript

Contact Us